VP1-2025: Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Final overall survival (OS) from the phase III TROPION-Breast01 trial

Barbara Pistilli, Komal Jhaveri, S-A. Im, S. Pernas Simon, Michelino De Laurentiis, Shuhua Wang, Noelia Martínez-Jáñez, Giuliano Santos Borges, David W. Cescon, Masaya Hattori, Yen‐Shen Lu, E. Hamilton, Qiang Zhang, J. Tsurutani, Kevin Kalinsky, Linhong Xu, Sabrina Khan, H.S. Rugo, B. Xu, Amit Bardia